ED Treatment denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for ed treatment are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your ED Treatment as Experimental

Aetna's experimental or investigational denial means that the specific ED treatment requested was determined to fall outside Aetna's definition of proven, generally accepted medical practice under their clinical policy bulletins (CPBs). This can occur when the treatment is a newer modality (for example, a device-based therapy, a regenerative treatment, or a pharmacological agent with a recent or limited FDA history), when the use is for an off-label indication, or when Aetna's CPB has not yet incorporated evidence the prescribing community considers established. Identifying which of these situations applies is essential before crafting an appeal.

## Why This Denial Is Appealable

Aetna's experimental designation is based on their internal evidence review, but it is not the final word. An independent IRO reviewer at the external review stage applies an objective assessment of whether the treatment is generally accepted in the medical community — a standard that can diverge from Aetna's internal policy when professional society guidelines or a recognized medical consensus support the treatment. If the prescribed ED treatment is supported by guidelines from an applicable professional society (such as the American Urological Association or another relevant specialty body), or is listed in a recognized medical compendium for the relevant indication, those sources provide the core of your appeal argument. Your prescriber's medical-necessity letter explaining the evidence basis is the other essential element.

## Federal Appeal Framework

ACA Section 2719 guarantees external review by an accredited IRO after Aetna's internal process is exhausted. This is particularly valuable in experimental denials because the IRO applies the "generally accepted in the medical community" standard rather than simply deferring to Aetna's CPB. ERISA Section 503 provides full-and-fair review rights for employer-sponsored plans. The external review window is approximately 4 months from the final internal denial. Expedited review (72 hours) is available when delay would seriously jeopardize your health or ability to regain maximum function.

## Concrete Appeal Steps and Timeline

1. Obtain Aetna's Clinical Policy Bulletin for the specific ED treatment — this document will state exactly what evidence standard the treatment must meet and what Aetna currently requires. 2. Identify the applicable professional society guideline that supports the treatment for your condition and ask your prescriber to reference it explicitly. 3. File the internal appeal within the deadline on your EOB, attaching the guideline, any compendium listings, and the prescriber letter. 4. Request external review if Aetna upholds the experimental denial internally — IROs overturn experimental denials at meaningful rates when guideline support is documented.

## Documentation to Gather

• Diagnosis confirmation: Chart notes with a precise diagnosis and description of how the condition has progressed or been inadequately managed with prior treatments.
• Prior treatment history: Records of other ED treatments tried, with dates and outcomes, establishing why the requested treatment is the appropriate next step.
• Professional society guideline or compendium reference: The specific recommendation or listing supporting use of this treatment for the relevant indication.
• Prescriber medical-necessity letter: A detailed letter citing the evidence basis, explaining why this treatment is appropriate for this patient, and directly addressing Aetna's experimental designation.
• Criteria-mapping table: Reproduce each criterion from Aetna's CPB in a table, and for each one document the specific chart fact or published evidence that satisfies it. Submit this structured mapping with your appeal.